Other Long Term Assets - SK Bioscience Co Ltd (KRX:302440)

Watchlist Manager

Watchlist

Price: 49 250 KRW 1.44% Market Closed

Market Cap: 3.9T KRW

SK Bioscience Co Ltd
Other Long-Term Assets

Quarterly

Annual

Adjust for Inflation

Balance Sheet

SK Bioscience Co Ltd
Other Long-Term Assets Peer Comparison

Company		Other Long-Term Assets	CAGR 3Y	CAGR 5Y	CAGR 10Y
	SK Bioscience Co Ltd KRX:302440	Other Long-Term Assets ₩130.7B	CAGR 3-Years 57%	CAGR 5-Years 60%	CAGR 10-Years N/A
	Celltrion Inc KRX:068270	Other Long-Term Assets ₩499.4B	CAGR 3-Years 126%	CAGR 5-Years 51%	CAGR 10-Years 76%
P	PharmaResearch Co Ltd KOSDAQ:214450	Other Long-Term Assets ₩7.9B	CAGR 3-Years 2%	CAGR 5-Years 16%	CAGR 10-Years 39%
	Alteogen Inc KOSDAQ:196170	Other Long-Term Assets ₩48.6B	CAGR 3-Years 109%	CAGR 5-Years 135%	CAGR 10-Years 52%
A	ABL Bio Inc KOSDAQ:298380	Other Long-Term Assets ₩181.6m	CAGR 3-Years -29%	CAGR 5-Years -16%	CAGR 10-Years N/A
D	DND PharmaTech Inc KOSDAQ:347850	Other Long-Term Assets ₩1.2B	CAGR 3-Years N/A	CAGR 5-Years N/A	CAGR 10-Years N/A

SK Bioscience Co Ltd
Glance View

Market Cap

3.9T KRW

Industry

Biotechnology

SK Bioscience Co Ltd., a remarkable enterprise carved out of the South Korean corporate landscape, operates at the dynamic intersection of biotechnology and pharmaceuticals. A part of the larger SK Group, one of Korea's leading conglomerates, the company was officially established in 2018 from SK Chemicals' life sciences division. Its primary focus is on developing and manufacturing vaccines, serving both public health needs locally and globally. The company has swiftly gained prominence for its role in the COVID-19 pandemic, particularly with the production of vaccines in collaboration with significant players such as AstraZeneca and Novavax. This strategic engagement loop has positioned SK Bioscience not only as a critical player in health crises management but also as a pivotal contributor to global health security. At the heart of SK Bioscience's business model is its ability to leverage cutting-edge research and robust manufacturing capabilities. The firm generates revenue through various channels, including product sales of its vaccines and other pharmaceuticals, contract manufacturing services, and partnerships with global entities, allowing it a diversified income stream. Its adeptness in innovation, underpinned by a strong R&D framework, ensures a steady development pipeline, supporting long-term growth ambitions. Through these strategic activities, SK Bioscience aligns itself with the SK Group’s broader commitment to social value and environmental, social, and governance (ESG) principles, fortifying its reputation as a company that not only seeks financial success but also endeavors to wield a positive global impact.

View SK Bioscience Co Ltd Analysis

Intrinsic Value

Overvaluation 22%

Intrinsic Value

Price

What is Intrinsic Value?

Economic Moat is a concept popularized by Warren Buffett to describe a company's durable competitive advantage. It represents the 'moat' that protects a company from competitors and helps it sustain profitability over the long term. Our analysis of the past 10 years showed that companies with a wide economic moat significantly outperformed the market, delivering +645% returns compared to +189% for the S&P 500.

Our research into Economic Moat performance spans the past 10 years and focuses on companies with a wide economic moat. For this analysis, we calculated the average stock price returns of these companies, comparing them to the performance of the S&P 500 index over the same period.

The results were compelling: wide moat stocks achieved a remarkable +645% average return, compared to +188% for the broader market. This difference highlights the long-term benefits of investing in businesses that can maintain their market position and pricing power over time.

Note: This research does not account for survivorship bias. Past performance is not indicative of future results.

Determining whether a company has an economic moat requires both a deep dive into financial metrics and a qualitative assessment of its competitive position. Our analysts conduct a rigorous evaluation that focuses on identifying structural advantages that enable a company to sustain profitability and defend its market share over the long term.

The process begins with an analysis of a company’s historical financial performance. We assess how consistently the company has generated returns above its cost of capital and whether those returns have been stable or improving. However, financial performance alone doesn’t reveal the full picture. To understand the sources of these advantages, we evaluate five key drivers of economic moats:

Network Effect: We analyze whether the value of a company’s product or service grows as its user base expands. Platforms like payment systems or marketplaces benefit from this self-reinforcing.

Switching Costs: We assess whether customers face significant costs or disruptions when switching to a competitor’s product or service. High switching costs create customer stickiness and provide pricing power.

Intangible Assets: Strong brands, patents, and regulatory licenses can protect a company’s market position by creating barriers for competitors or enabling premium pricing. For example, a well-recognized consumer brand may command higher customer loyalty and margins.

Efficient scale: Occurs when a market is optimally served by one or a few players, making it unprofitable for new entrants to compete. This typically happens in industries with high fixed costs or geographic constraints, such as utilities or pipelines.

Cost Advantage: Companies with structural cost advantages can produce goods or services at a lower cost than their competitors, enabling them to offer competitive pricing or maintain higher margins. These advantages often arise from economies of scale, superior supply chain management, or proprietary technology. Firms like Walmart leverage their massive scale to negotiate better terms with suppliers, allowing them to undercut competitors on price.

By examining these factors in combination with a company’s financial performance and market positioning, we classify each company into one of three categories:

This rigorous evaluation ensures that our moat ratings are both comprehensive and reliable, giving investors the tools they need to make well-informed, long-term decisions.

The AI Assistant may sometimes provide inaccurate information.

Make your own investment decisions or consult a licensed financial advisor.

SK Bioscience Co Ltd
KRX:302440

SK Bioscience Co Ltd
Other Long-Term Assets

SK Bioscience Co Ltd
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

SK Bioscience Co Ltd
Glance View

See Also

What is SK Bioscience Co Ltd's Other Long-Term Assets?

Other Long-Term Assets
130.7B KRW

What is SK Bioscience Co Ltd's Other Long-Term Assets growth rate?

Other Long-Term Assets CAGR 5Y
60%

Company

Help

Tools

Stocks

52 Week Range	35 850 60 100
Price Target

SK Bioscience Co Ltd KRX:302440

SK Bioscience Co Ltd Other Long-Term Assets

SK Bioscience Co Ltd Other Long-Term Assets Peer Comparison

Competitors Analysis Latest Figures & CAGR of Competitors

SK Bioscience Co Ltd Glance View

See Also

What is SK Bioscience Co Ltd's Other Long-Term Assets? Other Long-Term Assets 130.7B KRW

What is SK Bioscience Co Ltd's Other Long-Term Assets growth rate? Other Long-Term Assets CAGR 5Y 60%

Company

Help

Tools

Stocks

SK Bioscience Co Ltd
KRX:302440

SK Bioscience Co Ltd
Other Long-Term Assets

SK Bioscience Co Ltd
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

SK Bioscience Co Ltd
Glance View

What is SK Bioscience Co Ltd's Other Long-Term Assets?

Other Long-Term Assets
130.7B KRW

What is SK Bioscience Co Ltd's Other Long-Term Assets growth rate?

Other Long-Term Assets CAGR 5Y
60%